The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital

Amsterdam, Netherlands

The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital

Amsterdam, Netherlands
SEARCH FILTERS
Time filter
Source Type

Vugts G.,Catharina Hospital | Maaskant-Braat A.J.G.,Catharina Hospital | Voogd A.C.,Maastricht University | van Riet Y.E.A.,Catharina Hospital | And 7 more authors.
Annals of Surgical Oncology | Year: 2015

Purpose: Repeat sentinel node biopsy (SNB) is an alternative to axillary lymph node dissection (ALND) for axillary staging in recurrent breast cancer. This study was conducted to determine factors associated with technical success of repeat SNB. Methods: A total of 536 patients with locally recurrent nonmetastatic breast cancer underwent lymphatic mapping (LM) and repeat SNB in 29 Dutch hospitals. Results: A total of 179 patients previously underwent breast-conserving surgery (BCS) with SNB, 262 patients BCS with ALND and 61 patients mastectomy, 35 with SNB and 26 with ALND. Another 34 patients underwent breast surgery without axillary interventions. A repeat sentinel node (SN) was identified in 333 patients (62.1 %) and was successfully removed in 235 (53.5 %). The overall repeat SN identification rate was 62.1 %, varying from 35 to 100 % in the participating hospitals. Previous radiotherapy of the breast [odds ratio (OR) 0.16; 95 % confidence interval (CI) 0.03–0.84], subareolar tracer injection (OR 0.34; 95 % CI 0.16–0.73), and a 2-day LM protocol (OR 0.57; 95 % CI 0.33–0.97) after previous BCS were independently associated with failure of SN identification. Injection of a larger amount of tracer (>180 MBq) led to a higher identification rate (OR 4.40; 95 % CI 1.45–13.32). Conclusions: Repeat SNB is a technically feasible procedure for axillary staging in recurrent breast cancer patients. Previous radiotherapy appears to be associated with failure of SN identification. Injection with a larger amount of tracer (>180 MBq) leads to a higher identification rate; subareolar injection and a 2-day LM protocol after previous BCS appear to be less adequate. © 2015, Society of Surgical Oncology.


Brouwer O.R.,Leiden University | van der Poel H.G.,The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital | Bevers R.F.,Leiden University | van Gennep E.J.,Leiden University | Horenblas S.,The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital
Clinical and Translational Imaging | Year: 2016

This review aims to discuss the current state-of-the-art of sentinel node (SN) mapping in urological malignancies. The principles and methodological aspects of lymphatic mapping and SN biopsy in urological malignancies are reviewed. Literature search was restricted to English language. The references of the retrieved articles were examined to identify additional articles. The review also includes meta-analyses published in the past 5 years. SN biopsy for penile cancer is recommended by the European Association of Urology as the preferred staging tool for clinically node-negative patients with at least T1G2 tumours (level of evidence 2a, Grade B). The feasibility of SN biopsy in prostate cancer has been repeatedly demonstrated and its potential value is increasingly being recognised. However, conclusive prospective clinical data as well as consensus on methodology and patient selection are still lacking. For bladder, renal and testicular cancer, only few studies have been published, and concerns around high false-negative rates remain. Throughout the years, the uro-oncological field has portrayed a pivotal role in the development of the SN concept. Recent advances such as hybrid tracers and novel intraoperative detection tools such as fluorescence and portable gamma imaging will hopefully encourage prospectively designed clinical trials which can further substantiate the potential of the SN approach in becoming an integral part of staging in urological malignancies beyond penile cancer. © 2016, The Author(s).

Loading The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital collaborators
Loading The Netherlands Cancer InstituteAntoni van Leeuwenhoek Hospital collaborators